Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
NCT05322096 is registered in ClinicalTrials.gov with Gedeon Richter Plc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
- Lead sponsor
- Gedeon Richter Plc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 22, 2022
- Completion date
- April 10, 2024
- Enrollment
- 39 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.